Experimental Drug For Dwarfism In Children Shows Promising Early Results.

reports that BioMarin Pharmaceutical announced Wednesday that its experimental drug BMN 111 (vosoritide) which is “vying to become the first approved treatment for dwarfism,” resulted in “improved growth in children by a significant amount in a preliminary study.” The six-month results of the study showed that “the 10 children who got the highest dose of the drug grew at an average rate of 6.1 centimeters, or 2.4 inches, per year, about a 50 percent increase from the four centimeters per year they were growing before starting the drug,” which is “similar to that of a child without the condition.” Reuters (6/18, Shaji) also reports the story. http://www.nytimes.com/2015/06/18/business/drug-accelerated-growth-in-children-with-dwarfism-pharmaceutical-firm-says.html?_r=0